focus -WSS

focus

author：explore 2025-10-01 23:02:19 - browse：88677

Gavel and Stethoscope due process — District courts will make the first round of decisions soon on challenges to Medicare's drug price negotiation program. APStock

WASHINGTON — Pharmaceutical companies’ efforts to scuttle President Biden’s signature health care achievement, empowering Medicare to negotiate prescription drug prices, will soon face their first big tests.

District court judges could soon weigh in on the litany of court cases that major companies filed against the government — shedding light on whether drugmakers have any hope of postponing the first parts of the negotiation process, scrapping it entirely, or sending the issue up to the Supreme Court.

It’s a major moment for the Biden administration, too, as the White House ramps up its efforts to take credit for the new changes in the 2024 election. The first round of legal decisions will play out in the thick of campaign season, attorneys told STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Shifting the focus from loneliness to social health

knowledge

WSS

See how much Covid

Intellia reports positive results for its CRISPR

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Let's speed up science by embracing open access publishing

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Global cancer cases to surge 77% by 2050, WHO report says

focus

focus

explore

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Medicare proposal to cover medical devices draws a mixed reaction

Why CTE doesn’t keep Americans from enjoying the Super Bowl

The high cost of giving birth even with insurance

How to increase colonoscopy rates? Looks like an AI can help

As demand for Covid shots wanes, Moderna seeks its next success

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Trump demands the U.S. pay no more for drugs than other countries … again

Why CTE doesn’t keep Americans from enjoying the Super Bowl

entertainment

Top private equity targets in 2023: cardiology, clinical trials, lasers

Letters to First Opinion on caregivers, digital health, and more

Kaiser's Risant Health gobbled up Geisinger. Who is next?

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Problems with a popular proposal to regulate AI in health care

With trial win, GSK could get blood cancer drug back on market

leisure time

knowledge

knowledge

explore